TEE
PVLA

Tibra Equities Europe’s Palvella Therapeutics PVLA Stock Holding History

Tibra Equities Europe’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-818
Closed -$250K – 204
2021
Q2 		$250K Buy
+818
New +$179K 0.08% 213

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Tibra Equities Europe's PVLA Position: Q3 2021 in Review

Tibra Equities Europe sold out of Palvella Therapeutics (PVLA) in Q3 2021, closing a stake of 818 shares — an estimated $250K sold.

Tibra Equities Europe first reported a position in PVLA in Q2 2021 and held it in 1 quarter. The position peaked at $250K in Q2 2021. 75 funds tracked by Wall St. Rank hold PVLA as of Q3 2021.

  • Tibra Equities Europe reported no remaining Palvella Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Tibra Equities Europe sold 818 Palvella Therapeutics shares in Q3 2021, an estimated $250K.
  • Tibra Equities Europe first reported a position in Palvella Therapeutics in Q2 2021 and held it in 1 quarter.
  • Tibra Equities Europe's Palvella Therapeutics position peaked at $250K in Q2 2021.
  • 75 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q3 2021.

Based on Tibra Equities Europe's 13F filing for Q3 2021, filed 15 Nov 2021.